We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+18.67%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.32B
AUM Growth
+$20.1M
Cap. Flow
+$138M
Cap. Flow %
10.43%
Top 10 Hldgs %
45.62%
Holding
85
New
8
Increased
16
Reduced
15
Closed
5

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$19.7M
2
ALT icon
Altimmune
ALT
+$18.5M
3
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$17.5M
4
SWTX
SpringWorks Therapeutics
SWTX
+$17.4M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$15.9M

Top Sells

Rank Stock Value
1
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$54M
2
IGMS
IGM Biosciences
IGMS
+$10.8M
3
APLS
Apellis Pharmaceuticals
APLS
+$7.98M
4
PRAX icon
Praxis Precision Medicines
PRAX
+$7.68M
5
EWTX icon
Edgewise Therapeutics
EWTX
+$6.3M

Sector Composition

Rank Sector Weight
1 Healthcare 94.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCEL
76
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$571K 0.04%
319,057
-480,943
-60% -$1.01M
LENZ
77
LENZ Therapeutics
LENZ
$168M
$549K 0.04%
28,507
-515
-2% -$11.5K
IMV
78
DELISTED
IMV Inc. Common Shares
IMV
$155K 0.01%
23,437
– –
ORTX
79
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$150K 0.01%
25,665
– –
XFOR icon
80
X4 Pharmaceuticals
XFOR
$425M
$100K 0.01%
3,466
– –
BEAM icon
81
Beam Therapeutics
BEAM
$2.85B
– –
-90,045
Closed -$5.16M
DTIL icon
82
Precision BioSciences
DTIL
$207M
– –
-11,551
Closed -$1.07M
IGMS
83
DELISTED
IGM Biosciences
IGMS
– –
-402,200
Closed -$10.8M
ITOS
84
DELISTED
iTeos Therapeutics
ITOS
– –
-100,000
Closed -$3.22M
PRAX icon
85
Praxis Precision Medicines
PRAX
$9.73B
– –
-50,160
Closed -$7.68M
1 2 3
4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q2 2022 Portfolio in Review

As of Q2 2022, Cormorant Asset Management held 85 positions worth $1.32B, up 1.5% from $1.3B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Cormorant Asset Management deployed $138M of net new capital in Q2 2022, opening 8 new positions and adding to 16 existing holdings. Its largest new stake was Arcellx: 1,525,000 shares worth $27.6M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 98% a quarter earlier.

On the sell side, the largest reduction was Turning Point Therapeutics, Inc. Common Stock, an estimated $54M trimmed.

  • Cormorant Asset Management's largest Q2 2022 buy was Arcellx: 1,525,000 shares worth $27.6M.
  • Cormorant Asset Management added most to MoonLake Immunotherapeutics in Q2 2022, an estimated $17.5M increase.
  • Cormorant Asset Management's biggest Q2 2022 reduction was Turning Point Therapeutics, Inc. Common Stock, cutting an estimated $54M.
  • Cormorant Asset Management fully exited IGM Biosciences in Q2 2022, selling an estimated $10.8M.
  • Cormorant Asset Management's ten largest holdings make up 46% of its $1.32B portfolio in Q2 2022.
  • Cormorant Asset Management opened 8 new positions and closed 5 in Q2 2022.
  • Cormorant Asset Management's portfolio value rose 1.5% quarter-over-quarter to $1.32B.

Based on Cormorant Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.